| Item Type | Name |
|
Concept
|
Hepatitis C, Chronic
|
|
Academic Article
|
Long-term outcomes after treatment with interferon and ribavirin in HCV patients.
|
|
Academic Article
|
Evaluation of early null response to pegylated interferon and ribavirin as a predictor of therapeutic nonresponse in patients undergoing treatment for chronic hepatitis C.
|
|
Academic Article
|
Naives, nonresponders, relapsers: who is there left to treat?
|
|
Academic Article
|
Sticker shock and the price of new therapies for hepatitis C: is it worth it?
|
|
Academic Article
|
Daclatasvir in combination with asunaprevir and beclabuvir for hepatitis C virus genotype 1 infection with compensated cirrhosis.
|
|
Academic Article
|
Evaluation of Hepatitis C Patients in the Direct-Acting Antiviral Era.
|
|
Academic Article
|
HCV Council--critical appraisal of data: recommendations for clinical practice in a rapidly evolving therapeutic landscape.
|
|
Academic Article
|
Sofosbuvir and Velpatasvir for HCV Genotype 2 and 3 Infection.
|
|
Academic Article
|
Safety and Efficacy of Ombitasvir/Paritaprevir/Ritonavir Plus Dasabuvir With or Without Ribavirin in HCV-Infected Patients Taking Concomitant Acid-Reducing Agents.
|
|
Academic Article
|
Ribavirin-Free Regimen With Sofosbuvir and Velpatasvir Is Associated With High Efficacy and Improvement of Patient-Reported Outcomes in Patients With Genotypes 2 and 3 Chronic Hepatitis C: Results From Astral-2 and -3 Clinical Trials.
|
|
Academic Article
|
Characterization of nonrapid virologic response patients infected with HCV genotype 1 who may relapse after standard therapy with peginterferon plus ribavirin.
|
|
Academic Article
|
Hepatitis C: management of side effects in the era of direct-acting antivirals.
|
|
Academic Article
|
Efficacy of Sofosbuvir, Velpatasvir, and GS-9857 in Patients With?Genotype 1 Hepatitis C Virus Infection in an Open-Label, Phase 2 Trial.
|
|
Academic Article
|
Updates on hepatitis C virus therapy in the direct-acting antiviral era.
|
|
Academic Article
|
Patient engagement and study design of PROP UP: A multi-site patient-centered prospective observational study of patients undergoing hepatitis C treatment.
|
|
Academic Article
|
Resistance analysis in patients with genotype 1-6 HCV infection treated with sofosbuvir/velpatasvir in the phase III studies.
|
|
Academic Article
|
Psychometric properties of the PROMIS short form measures in a U.S. cohort of 961 patients with chronic hepatitis C prescribed direct acting antiviral therapy.
|
|
Academic Article
|
Hepatitis C Virus Infection Care Pathway-A Report From the American Gastroenterological Association Institute HCV Care Pathway Work Group.
|
|
Academic Article
|
Potential consequences of healthcare recommendations: a focus on the U.S. Preventive Services Task Force.
|
|
Academic Article
|
Glecaprevir/Pibrentasvir Treatment in Liver or Kidney Transplant Patients With Hepatitis C Virus Infection.
|
|
Academic Article
|
A comprehensive assessment of patient reported symptom burden, medical comorbidities, and functional well being in patients initiating direct acting antiviral therapy for chronic hepatitis C: Results from a large US multi-center observational study.
|
|
Academic Article
|
Cost-effectiveness of Universal Hepatitis C Virus Screening of Pregnant Women in the United States.
|
|
Academic Article
|
Patient-reported symptoms during and after direct-acting antiviral therapies for chronic hepatitis C: The PROP UP study.
|
|
Academic Article
|
HCV in Women and Pregnancy.
|
|
Academic Article
|
Hepatitis C remains leading indication for listings and receipt of liver transplantation for hepatocellular carcinoma.
|
|
Academic Article
|
Medication Non-adherence in a Prospective, Multi-center Cohort Treated with Hepatitis C Direct-Acting Antivirals.
|
|
Academic Article
|
Reply to: "Patient-reported symptoms during direct-acting antiviral treatment: A real-life study in HIV-HCV coinfected patients (ANRS?CO13 HEPAVIH)".
|
|
Academic Article
|
Changing epidemiology, implications, and recommendations for hepatitis C in women of childbearing age and during pregnancy.
|
|
Academic Article
|
Patient-reported outcomes 12?months after hepatitis C treatment with direct-acting antivirals: Results from the PROP UP study.
|
|
Academic Article
|
Epidemiology and Clinical Characteristics of Individuals with Hepatitis C Virus Infection in the United States, 2017-2019.
|